Balancing clinical evidence in the context of a pandemic
- 5 February 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 39 (3), 270-274
- https://doi.org/10.1038/s41587-021-00834-6
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid TumorsClinical Cancer Research, 2019
- Adaptive Designs for Clinical TrialsThe New England Journal of Medicine, 2016
- Precision Oncology: The UC San Diego Moores Cancer Center PREDICT ExperienceMolecular Cancer Therapeutics, 2016
- Personalized medicine: Time for one-person trialsNature, 2015
- Cancer research in the United States: Dying by a thousand paper cutsCancer, 2013
- Equipoise Lost: Ethics, Costs, and the Regulation of Cancer Clinical ResearchJournal of Clinical Oncology, 2010
- Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized TrialJournal of Clinical Oncology, 2009
- In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquineBiochemical and Biophysical Research Communications, 2004
- Rules of Evidence and Clinical Recommendations on the Use of Antithrombotic AgentsSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1989